Difference between revisions of "Establishing a novel neural tissue deformation biomarker for type 1 chiari malformation"
(Created page with "thumb|right|400px|Figure 1. MR measurement of the cerebrospinal fluid spaces in a healthy adult female. ==Team== *Bryn Martin ==Problem== Here....") |
|||
(12 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | [[ | + | [[File:Chiari_MR.jpg | thumb | right | MR measurement of Chiari patient.]] |
==Team== | ==Team== | ||
*[[Bryn Martin]] | *[[Bryn Martin]] | ||
+ | *[[Gwendolyn Williams]] | ||
==Problem== | ==Problem== | ||
− | + | ||
+ | Untreated Type 1 Chiari malformation (CM1) is a devastating neurological disorder that can be treated by a high risk and costly brain operation. Since the decision to operate is often based on common symptoms, such as severe headache, along with a single imaging measure of cerebellar position that is commonly recognized as inadequate, the concern for under- and especially over-treatment is high. With an estimated 4-5 million in the US carrying the current inadequate anatomical marker of cerebellar descent >5 mm below the foramen magnum, and approximately 97% of these millions demonstrating only minimal symptoms or symptoms with other unrelated etiologies, there is a potential for tens of thousands of inappropriate operations with corresponding bad outcomes, while others suffer untreated. The CM1 public critically needs a biomarker that better reflects CM1 pathophysiology, allowing physicians a more accurate surgical selection. | ||
==Study Information== | ==Study Information== |
Latest revision as of 22:08, 4 August 2020
Team
Problem
Untreated Type 1 Chiari malformation (CM1) is a devastating neurological disorder that can be treated by a high risk and costly brain operation. Since the decision to operate is often based on common symptoms, such as severe headache, along with a single imaging measure of cerebellar position that is commonly recognized as inadequate, the concern for under- and especially over-treatment is high. With an estimated 4-5 million in the US carrying the current inadequate anatomical marker of cerebellar descent >5 mm below the foramen magnum, and approximately 97% of these millions demonstrating only minimal symptoms or symptoms with other unrelated etiologies, there is a potential for tens of thousands of inappropriate operations with corresponding bad outcomes, while others suffer untreated. The CM1 public critically needs a biomarker that better reflects CM1 pathophysiology, allowing physicians a more accurate surgical selection.
Study Information
We are currently enrolling subjects for this study. This study involves 1 non-invasive MRI scan at Inland Imaging in Spokane, WA. Subjects with diagnosed ALS and age/gender matched controls are needed. Participants must be able to lay on their back in the MRI scanner for the 1-hour scanning period. We can provide the MR images to participants free of charge. Please click on the links below to learn more.
- Study flyer: File:Flyer chiari.pdf
- Study informed consent: File:Informed consent chiari.pdf